Andy Chen

Q: What is Andy Chen's success rate?

Andy Chen currently has a success rate of 85.59570498598914.

Q: What is the average return of Andy Chen's calls?

Their stock ratings have generated an average return of 31.1553009680104.

Wolfe Research | Healthcare

Andy Chen is an analyst from Wolfe Research specializing in the Healthcare sector. Ranked #1005 out of 4716 analysts, they have issued 17 stock ratings with a success rate of 85.60% and an average return of 31.16%.

With 17 ratings to date, Andy Chen is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 85.60% and an average return of 31.16%, highlighting promising potential as their track record develops further.

#1005

Out of 4716

Total Ratings

+85.60%

Success Rate

+31.16%

Average Return

Recent Ratings Analysis

SRPT

Buy

Jul 09, 2026

Target

$27.00

Current

$20.21

Performance

—

Andy Chen rated SRPT as Outperform on Jul 09, 2026, setting a price target of 27. Shares have remained stable near 20.21, leaving the 27 target still in play.

PHVS

Buy

Apr 09, 2026

Target

$42.00

Current

$35.92

Performance

32.71%

On Apr 09, 2026, PHVS was given a Outperform rating by Andy Chen, with a target price of 42. The stock rallied 32.71% after the rating, narrowing the gap to the target of 42 and validating the bullish stance.

PALI

Buy

Apr 09, 2026

Target

$7.00

Current

$2.05

Performance

3.54%

PALI received a Outperform rating from Andy Chen on Apr 09, 2026, aiming for 7. Price action was muted, as shares hovered around 2.05 despite the bullish outlook.

DNTH

Buy

Apr 09, 2026

Target

$98.00

Current

$98.07

Performance

6.99%

On Apr 09, 2026, Andy Chen published a Outperform outlook on DNTH, with a target of 98. Shares gained 6.99%, underscoring the accuracy of the bullish outlook toward 98.

AVTX

Buy

Apr 09, 2026

Target

$48.00

Current

$19.21

Performance

35.19%

Andy Chen on Apr 09, 2026 assigned AVTX a Outperform rating, with a price target of 48. The Buy call aligned well with market performance, producing a gain of 35.19%.

MLTX

Buy

Mar 23, 2026

Target

$24.00

Current

$19.07

Performance

13.04%

On Mar 23, 2026, Andy Chen reaffirmed MLTX with a Outperform rating, targeting 24. The recommendation was supported by strong follow-through as the stock rose from 19.07 to 19.07.

VERA

Buy

Mar 11, 2026

Target

$88.00

Current

$42.43

Performance

0.93%

VERA was rated Outperform by Andy Chen on Mar 11, 2026, with a price objective of 88. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

APGE

Hold

Jan 07, 2026

Target

—

Current

$133.25

Performance

68.78%

On Jan 07, 2026, Andy Chen initiated coverage on APGE with a Peer Perform rating and target of null. The Hold stance underestimated the stock’s strength as it gained 68.78%.

KYMR

Hold

Jan 06, 2026

Target

—

Current

$114.16

Performance

55.40%

Andy Chen issued a Peer Perform recommendation for KYMR on Jan 06, 2026, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

IMVT

Buy

Jan 06, 2026

Target

$50.00

Current

$40.31

Performance

55.64%

On Jan 06, 2026, IMVT was evaluated by Andy Chen, who gave a Outperform rating and target of 50. This case illustrates how a timely bullish rating can translate into tangible gains of 55.64%.

VRTX

Buy

Jan 06, 2026

Target

$548.00

Current

$498.43

Performance

6.42%

Andy Chen rated VRTX as Outperform on Jan 06, 2026, setting a price target of 548. The call has proven timely, with shares rising 6.42% toward the price target of 548.

ARGX

Hold

Nov 24, 2025

Target

—

Current

$915.30

Performance

0.94%

On Nov 24, 2025, ARGX was given a Peer Perform rating by Andy Chen, with a target price of null. Market indecision, reflected in sideways trading near 915.3, supported the cautious call.

NTLA

Hold

Nov 12, 2025

Target

—

Current

$16.84

Performance

77.45%

NTLA received a Peer Perform rating from Andy Chen on Nov 12, 2025, aiming for null. Investors saw gains of 77.45% that the cautious stance didn’t fully capture.

APLS

Hold

Nov 06, 2025

Target

—

Current

$41.03

Performance

108.17%

On Nov 06, 2025, Andy Chen published a Peer Perform outlook on APLS, with a target of null. The Hold call missed some of the bullish momentum as shares advanced toward null.

AKRO

Hold

Oct 10, 2025

Target

—

Current

$54.65

Performance

1.43%

Andy Chen on Oct 10, 2025 assigned AKRO a Peer Perform rating, with a price target of null. The Hold stance reflected consolidation, as shares held near 54.65.

ETNB

Hold

Sep 19, 2025

Target

—

Current

$14.84

Performance

-0.20%

On Sep 19, 2025, Andy Chen reaffirmed ETNB with a Peer Perform rating, targeting null. The neutral call matched muted market action of -0.20%.

ALNY

Hold

Aug 04, 2025

Target

—

Current

$323.50

Performance

-22.90%

ALNY was rated Peer Perform by Andy Chen on Aug 04, 2025, with a price objective of null. Investors who stayed cautious avoided some of the 22.90% decline.

VRNA

Buy

Jul 01, 2025

Target

$170.00

Current

$106.91

Performance

18.16%

On Jul 01, 2025, Andy Chen initiated coverage on VRNA with a Outperform rating and target of 170. The stock’s climb of 18.16% since the call highlights the foresight in the rating.

RNA

Buy

Jun 17, 2025

Target

$55.00

Current

$13.37

Performance

-54.46%

Andy Chen issued a Outperform recommendation for RNA on Jun 17, 2025, price target set at 55. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

BBIO

Buy

Jun 17, 2025

Target

$49.00

Current

$78.33

Performance

95.48%

On Jun 17, 2025, BBIO was evaluated by Andy Chen, who gave a Outperform rating and target of 49. This case illustrates how a timely bullish rating can translate into tangible gains of 95.48%.

CRNX

Hold

Feb 04, 2025

Target

—

Current

$83.49

Performance

106.66%

Andy Chen rated CRNX as Peer Perform on Feb 04, 2025, setting a price target of null. Despite the Hold call, shares climbed 106.66% to 83.49, revealing unexpected momentum.

ANAB

Buy

Feb 04, 2025

Target

—

Current

$65.35

Performance

295.82%

On Feb 04, 2025, ANAB was given a Outperform rating by Andy Chen, with a target price of null. The stock rallied 295.82% after the rating, narrowing the gap to the target of null and validating the bullish stance.

ZBIO

Buy

Feb 04, 2025

Target

$19.00

Current

$28.77

Performance

275.52%

ZBIO received a Outperform rating from Andy Chen on Feb 04, 2025, aiming for 19. Momentum has favored the Buy call, with shares climbing from 28.765 to 28.765, rewarding those who trusted the recommendation.

ORKA

Buy

Feb 04, 2025

Target

$20.00

Current

$84.40

Performance

493.95%

On Feb 04, 2025, Andy Chen published a Outperform outlook on ORKA, with a target of 20. Shares gained 493.95%, underscoring the accuracy of the bullish outlook toward 20.

INCY

Buy

Oct 01, 2024

Target

—

Current

$117.26

Performance

72.29%

Andy Chen on Oct 01, 2024 assigned INCY a Outperform rating, with a price target of null. The Buy call aligned well with market performance, producing a gain of 72.29%.

CLDX

Hold

Sep 27, 2024

Target

—

Current

$38.96

Performance

17.35%

On Sep 27, 2024, Andy Chen reaffirmed CLDX with a Peer Perform rating, targeting null. Market strength beyond 38.96 went further than the conservative outlook suggested.

VRDN

Buy

Jun 11, 2024

Target

—

Current

$19.86

Performance

47.55%

VRDN was rated Outperform by Andy Chen on Jun 11, 2024, with a price objective of null. A bullish response from the market helped close the gap of -19.86 to the target.

MDGL

Buy

Jun 11, 2024

Target

—

Current

$565.40

Performance

93.64%

On Jun 11, 2024, Andy Chen initiated coverage on MDGL with a Outperform rating and target of null. The stock’s climb of 93.64% since the call highlights the foresight in the rating.

RAPT

Hold

May 14, 2024

Target

—

Current

$58.01

Performance

81.27%

Andy Chen issued a Peer Perform recommendation for RAPT on May 14, 2024, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

Frequency Asked Questions

Who is Andy Chen?

Andy Chen is an analyst from Wolfe Research specializing in the Healthcare sector.

What is Andy Chen's success rate?

Andy Chen currently has a success rate of +85.60%.

How many ratings has Andy Chen issued?

Andy Chen has issued 17 stock ratings so far.

What is the average return of Andy Chen's calls?

Their stock ratings have generated an average return of +31.16%.

What is Andy Chen's ranking?

Andy Chen is ranked #1005 out of 4716 analysts.

What types of ratings does Andy Chen give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andy Chen?

You can follow Andy Chen by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andy Chen?

Their latest rating was a Buy on SRPT issued on 2026-07-09.